

<b>INFORMATION DISCLOSURE STATEMENT</b> <b>37 C.F.R. § 1.97(b)</b>		ATTORNEY DOCKET NO. <b>70078.0020USWO</b>	
		U.S. APPLICATION SERIAL NO. <b>10/591642</b>	CONFIRMATION NO. <b>New</b>
		FILING DATE <b>Herewith</b>	
INVENTOR(S) <b>Renato MONTEIRO et al.</b>		EXAMINER <b>New</b>	GROUP ART UNIT <b>New</b>
TITLE OF APPLICATION <b>MONOVALENT LIGAND OF THE Fc<math>\alpha</math>RI RECEPTOR AS AN ANTI-INFLAMMATORY AGENT</b>			

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. All of the items listed on the Form 1449 were recently cited in an International Search Report mailed June 6, 2006.

This statement should be considered because it is submitted within three months of the date of entry of the national stage in an international application (37 C.F.R. § 1.491). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Enclosed for the Examiner's information is a copy of the International Search Report.

**Certification Under 37 C.F.R. §1.97(e)(1)**

The undersigned hereby certifies that each item of information listed on the enclosed Form 1449 was first cited in a communication from a foreign patent office in a counterpart foreign application within three months of filing this statement.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or


RECEIVED 05 SEP 2006

otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,  
MERCHANT & GOULD, P.C.



William E. Beaumont  
Registration No. 30,996

September 5, 2006

Date

P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
Telephone No. (202) 326-0300  
Facsimile No. (202) 326-0778

**23552**

Patent & Trademark Office

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<h2 style="margin: 0;">INFORMATION DISCLOSURE STATEMENT (PTO 1449)</h2>		ATTORNEY DOCKET NO. <b>70078.0020USWO</b>	
		U.S. APPLICATION SERIAL NO. <b>10/591642</b>	CONFIRMATION NO. <b>New</b>
		FILING DATE <b>Herewith</b>	
INVENTOR(S) <b>Renato MONTEIRO et al.</b>		EXAMINER <b>New</b>	GROUP ART UNIT <b>New</b>
TITLE OF APPLICATION <b>MONOVALENT LIGAND OF THE FcαRI RECEPTOR AS AN ANTI-INFLAMMATORY AGENT</b>			

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	6,018,031	01/25/2000	Shen et al.			

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B	99/41285	08/19/1999	WIPO				
	C	02/064634	08/22/2002	WIPO				
	D	99/28349	06/10/1999	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
E	MORTON, H Craig et al., "CD89: the Human Myeloid IgA Fc Receptor," ARCHIVUM IMMUNOLGIAE ET THERAPIAE EXPERIMENTALIS, vol. 49, no. 3, 2001, pages 217-229, XP009035083, PL ISSN: 0004-069X
F	PCT International Search Report dated June 6, 2006
G	
H	
I	
J	
K	
L	
M	
N	
O	
P	
Q	
R	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if the reference is considered, whether or not the citation is in conformance with MPEP 609. Draw a line through the citation if it is not in conformance and it is not considered. Include a copy of this form with the next communication to the Applicant.	